Fortress Biotech (FBIO) Asset Writedowns and Impairment (2014 - 2025)
Fortress Biotech (FBIO) posted quarterly Asset Writedowns and Impairment of $170000.0 for Q4 2025, down 94.07% year-over-year from $2.9 million in Q4 2024, and up 200.0% quarter-over-quarter from -$170000.0 in Q3 2025.
Powered by 
Analysis
Fortress Biotech (FBIO) Asset Writedowns and Impairment (2014 - 2025) Analysis & Trends
Fortress Biotech's Asset Writedowns and Impairment history runs 10 years deep, the most recent figure standing at $170000.0 for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment fell 94.07% year-over-year to $170000.0; the TTM figure through Sep 2025 stood at $2.7 million (down 54.84% YoY), while the FY2024 annual figure was $3.7 million, up 17.47% from the prior year.
- Asset Writedowns and Impairment for Q4 2025 stood at $170000.0, up from -$170000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $2.9 million in Q4 2024, with the low at -$2.4 million in Q3 2023.
- The 5-year median for Asset Writedowns and Impairment is $92500.0 (2021), against an average of $483500.0.
- Peak annual rise in Asset Writedowns and Impairment reached 8922.58% in 2023, while the deepest fall reached 5502.22% in 2023.
- Fortress Biotech's Asset Writedowns and Impairment stood at $115000.0 in 2021, then jumped by 146.96% to $284000.0 in 2022, then surged by 833.45% to $2.7 million in 2023, then gained by 8.22% to $2.9 million in 2024, then sank by 94.07% to $170000.0 in 2025.
- Business Quant data shows FBIO's Asset Writedowns and Impairment at $170000.0 in Q4 2025, -$170000.0 in Q3 2025, and -$195000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn |
| 10 | Fortress Biotech | 86.15 Mn | -110.42 Mn | 12.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -41,000.00 |
| Sep 30, 2025 | 76,000.00 |
| Jun 30, 2025 | -441,000.00 |
| Mar 31, 2025 | 195,000.00 |
| Dec 31, 2024 | 1.04 Mn |
| Jun 30, 2024 | 2.64 Mn |
| Mar 31, 2024 | 6,000.00 |
| Jun 30, 2023 | 3.14 Mn |
| Mar 31, 2023 | 126,000.00 |
| Dec 31, 2022 | 274,000.00 |
| Sep 30, 2022 | 55,000.00 |
| Jun 30, 2022 | 31,000.00 |
| Mar 31, 2022 | -76,000.00 |
| Dec 31, 2021 | 115,000.00 |
| Sep 30, 2021 | -10,000.00 |
| Jun 30, 2021 | -127,000.00 |
| Mar 31, 2021 | 70,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Sep 30, 2020 | -29,000.00 |
| Jun 30, 2020 | 76,000.00 |